Computed Tomography Arteriograms (CTA) Volume Dose Reduction Study

NACompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

November 30, 2018

Conditions
Aortic AneurysmContrast Induced NephropathyAortic and Arterial Anomalies
Interventions
DRUG

Low Dose Contrast (Omnipaque) 40mL

The patient will be administered a low dose, 40mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.

DRUG

Low Dose Contrast (Omnipaque) 50 mL

The patient will be administered a low dose, 50mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.

Trial Locations (1)

17033

Penn State Milton S. Hershey Medical Center, Hershey

All Listed Sponsors
lead

Milton S. Hershey Medical Center

OTHER

NCT02669784 - Computed Tomography Arteriograms (CTA) Volume Dose Reduction Study | Biotech Hunter | Biotech Hunter